Skip to main content

Efficacy of Agomelatine in Depressive Disorders with Anxiety

An open six-week study of the efficacy of agomelatine was performed in 35 patients with single depressive episodes or recurrent depression (ICD-10 diagnoses) and clinically severe anxiety. Agomelatine was found to be highly effective and safe in the treatment of mild and moderate depression combined with anxiety disorders. Decreases in the severity of the symptoms of depression and sleep disorders were seen from treatment week 1, with reductions in anxiety from treatment week 2. By the end of the study, therapeutic effects were seen in 71.9% of patients and the remission criteria were achieved in 68.8% of patients.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    O. P. Vertogradova, “Possible approaches to the typology of depression,” in: Depression (psychopathology, pathogenesis), Moscow (1980), pp. 9–15.

  2. 2.

    V. N. Krasnov, Affective Spectrum Disorders, Moscow (2011), pp. 146–156.

  3. 3.

    S. N. Mosolov, E. G. Kostyukova, A. V. Gorodinchev, et al., “Efficacy and tolerance of agomelatine in depressive states,” 15, 15–24 (2011).

  4. 4.

    A. A. Pribytkov, “Comparative analysis of the antidepressant activity and effects on sleep disorders of agomelatine (Valdoxan) and fluvoxamine (Fevarin),” Obozr. Psikhiatr. Med. Psikhol. im. Bekhtereva, No. 4, 38–40 (2010).

  5. 5.

    L. B. Allen, K. S. White, and D. H. Barlow, “Cognitive behavior therapy (CBT) for panic disorder: relationship of anxiety and depression comorbidity with treatment outcomes,” J. Psychopathol. Behav. Assess., 32, No. 2, 185–192 (2010).

    Article  PubMed Central  PubMed  Google Scholar 

  6. 6.

    D. S. Baldwin, C. Allgulander, B. Bandelow, et al., “An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder,” World J. Biol. Psychiatry, 13, No. 7, 510–516 (2012).

    Article  PubMed  Google Scholar 

  7. 7.

    B. Bandelow, J. Zohar, E. Hollander, et al., “World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision,” World J. Biol. Psychiatry, 9, No. 4, 248–312 (2008).

    Article  PubMed  Google Scholar 

  8. 8.

    D. H. Barlow and L. A. Campbell, “Mixed anxiety-depression and its implications for models of mood and anxiety disorders,” Comp. Psychiatry, 41, No. 2, 55–60 (2000).

    Article  CAS  Google Scholar 

  9. 9.

    J. Das-Munshi, D. Goldberg, P. Bebbington, et al., “Public health significance of mixed anxiety and depression: beyond current classification,” Brit. J. Psychiatry, 192, No. 3, 171–177 (2008).

    Article  Google Scholar 

  10. 10.

    J. R. Davidson, “First-line pharmacotherapy approaches for generalized anxiety disorder,” J. Clin. Psychiatry, 70, No. 2, 25–31 (2009).

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    D. R. Dolnak, “Treating patients for comorbid depression, anxiety disorders, and somatic illnesses,” J. Am. Osteopath. Assoc., No. 2, 1–8 (2006).

  12. 12.

    E. Driessen and S. D. Hollon, “Cognitive behavioral therapy for mood disorders: efficacy, moderators and mediators,” Psychiatr. Clin. North Am., 33, No. 3, 537–555 (2010).

    Article  PubMed Central  PubMed  Google Scholar 

  13. 13.

    P. S. Foroushani, J. Schneider, and N. Assareh, “Meta-review of the effectiveness of computerized CBT in treating depression,” BMC Psychiatry , No. 11, 131 (2011).

  14. 14.

    G. Gartlehner, R. A. Hansen, and L. C. Morgan, et al., “Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis,” Ann. Intern. Med., 155, No. 11, 772–785 (2011).

    Article  PubMed  Google Scholar 

  15. 15.

    A. Hale, R. M. Corral, C. Mencacci, et al., “Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study,” Int. Clin. Psychopharmacol., 25, No. 6, 305–314 (2010).

    Article  PubMed  Google Scholar 

  16. 16.

    S. G. Hofman and J. A. Smits, “Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials,” J. Clin. Psychiatry, 69, No. 4, 621–632 (2008).

    Article  Google Scholar 

  17. 17.

    H. E. Hollander, “Antidepressants in the treatment of depression: the clinician and the controversy,” Am. J. Clin. Hypn., 55, No. 3, 230–235 (2013).

    Article  PubMed  Google Scholar 

  18. 18.

    S. Kasper, G. Hajak, K. Wulff, et al., “Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline,” J. Clin. Psychiatry, 71, No. 2, 109–120 (2010).

    Article  CAS  PubMed  Google Scholar 

  19. 19.

    S. H. Kennedy, S. Rizvi, K. Fulton, et al., “A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR,” J. Clin. Psychopharmacol., 28, No. 3, 329–333 (2008).

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    S. H. Kennedy and E. Emsley, “Placebo-controlled trial of agomelatine in the treatment of major depressive disorder,” Eur. Neuropsychopharmacol., 16, No. 2, 93–100 (2006).

    Article  CAS  PubMed  Google Scholar 

  21. 21.

    R. J. Kuzel, “Treating comorbid depression and anxiety,” J. Fam. Pract., 43, 45–53 (1996).

    Google Scholar 

  22. 22.

    P. Lemoine, C. Guilleminault, and E. Alvarez, “Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine,” J. Clin. Psychiatry, 68, No. 11, 1723–1732 (2007).

    Article  CAS  PubMed  Google Scholar 

  23. 23.

    M. N. Levitan, M. Papelbaum, and A. E. Nardi, “A review of preliminary observations on agomelatine in the treatment of anxiety disorders,” Exp. Clin. Psychopharmacol., 20, No. 6, 504–509 (2012).

    Article  CAS  PubMed  Google Scholar 

  24. 24.

    H. Lôo, A. Hale, and H. D’haenen, “Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study,” Int. Clin. Psychopharmacol., 17, No. 5, 239–247 (2002).

    Article  PubMed  Google Scholar 

  25. 25.

    A. D. Lopez, C. D. Mathers, M. Ezzati, et al., “Global and regional burden of disease and risk factor, 2001: systematic analysis of population health data,” Lancet, 367, 1747–1757 (2006).

    Article  PubMed  Google Scholar 

  26. 26.

    A. McIntyre, A. Gendron, and A. McIntyre, “Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study,” Depress. Anxiety, 24, No. 7, 487–494 (2007).

    Article  CAS  PubMed  Google Scholar 

  27. 27.

    M. J. Millan, M. Brocco, A. Gobert, et al., “Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade,” Psychopharmacology, 177, No. 4, 448–458 (2005).

    Article  CAS  PubMed  Google Scholar 

  28. 28.

    N. Mor and D. Haran, “Cognitive-behavioral therapy for depression,” Isr. J. Psychiatry Relat. Sci., 46, No. 4, 269–273 (2009).

    PubMed  Google Scholar 

  29. 29.

    J. P. Olié and S. Kasper, “Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder,” Int. J. Neuropsychopharmacol., 10, No. 5, 661–673 (2007).

    PubMed  Google Scholar 

  30. 30.

    M. H. Pollack, “Comorbid anxiety and depression,” J. Clin. Psychiatry, 66, No. 8, 22–29 (2005).

    CAS  PubMed  Google Scholar 

  31. 31.

    A. Qaseem, V. Snow, T. D. Denberg, et al., “Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians,” Ann. Intern. Med., 149, No. 10, 725–733 (2008).

    Article  PubMed  Google Scholar 

  32. 32.

    M. A. Quera-Salva, P. Lemoine, and C. Guilleminault, “Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients,” Hum. Psychopharmacol., 25, No. 3, 222–229 (2010).

    Article  CAS  PubMed  Google Scholar 

  33. 33.

    S. M. Stahl, M. Fava, M. H. Trivedi, et al., “Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial,” J. Clin. Psychiatry, 71, No. 5, 616–626 (2010).

    Article  CAS  PubMed  Google Scholar 

  34. 34.

    D. J. Stein, A. Ahokas, C. Albarran, et al., “Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study,” J. Clin. Psychiatry, 73, No. 7, 1002–108 (2012).

    Article  CAS  PubMed  Google Scholar 

  35. 35.

    D. J. Stein, A. A. Ahokas, and C. de Bodinat, “Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study,” J. Clin. Psychopharmacol., 28, No. 5, 561–566 (2008).

    Article  CAS  PubMed  Google Scholar 

  36. 36.

    F. Wedegaertner, S. Arnhold-Kerri, N. A. Sitgtaro, et al., “Depression- and anxiety-related sick leave and the risk of permanent disability and mortality in the working population in Germany: a cohort study,” BMC Public Health, 13, No. 1, 145 (2013).

    Article  PubMed Central  PubMed  Google Scholar 

  37. 37.

    S. Wetzler and M. M. Katz, “Problems with the differentiation of anxiety and depression,” J. Psychiat. Res., 23,. No. 1, 1–12 (1989).

    Article  CAS  PubMed  Google Scholar 

  38. 38.

    A. S. Young, R. Klap, R. Shoai, et al., “Persistent depression and anxiety in the United States: prevalence and quality of care,” Psychiatr. Serv., 59, No. 12, 1391–1398 (2008).

    Article  PubMed Central  PubMed  Google Scholar 

  39. 39.

    J. Zajecka, A. Schatzberg, S. Stahl, et al., “Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial,” J. Clin. Psychopharmacol., 30, No. 2, 135–144 (2010).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to A. A. Pribytkov.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 113, No. 11, Iss 2, Depression, pp. 53–58, November, 2013.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pribytkov, A.A., Panova, N.B., Popova, Y.V. et al. Efficacy of Agomelatine in Depressive Disorders with Anxiety. Neurosci Behav Physi 45, 393–397 (2015). https://doi.org/10.1007/s11055-015-0087-7

Download citation

Keywords

  • depression
  • anxiety
  • agomelatine
  • sleep disorders